Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7780]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
Emerging post-transplant therapeutic options for relapsed Hodgkin lymphoma
Dr Astrid Pavlovsky - Center for Haematology, Buenos Aires, Argentina
Emerging post-transplant therapeutic options for relapsed Hodgkin lymphoma ( Dr Astrid Pavlovsky - Center for Haematology, Buenos Aires, Argentina )
15 Jun 2018
Ribosomal lesions promote oncogenic mutagenesis
Dr Sergey Sulima - Katholieke Universiteit Leuven, Lueven, Belgium
Ribosomal lesions promote oncogenic mutagenesis ( Dr Sergey Sulima - Katholieke Universiteit Leuven, Lueven, Belgium )
15 Jun 2018
Rituximab in combination therapies for FL: Interim results
Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France
Rituximab in combination therapies for FL: Interim results ( Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France )
15 Jun 2018
Improved OS with obinutuzumab in the CLL11 study
Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany
Improved OS with obinutuzumab in the CLL11 study ( Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany )
15 Jun 2018
Disease control in advanced Hodgkin lymphoma
Dr Olivier Casasnovas - CHU de Dijon, Dijon, France
Disease control in advanced Hodgkin lymphoma ( Dr Olivier Casasnovas - CHU de Dijon, Dijon, France )
15 Jun 2018
Interim results of RELEVANCE trial in follicular lymphoma
Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France
Interim results of RELEVANCE trial in follicular lymphoma ( Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France )
15 Jun 2018
Mapping 3D genome dynamics in B cells
Dr José Ignacio Martin-Subero - University of Barcelona, Barcelona, Spain
Mapping 3D genome dynamics in B cells ( Dr José Ignacio Martin-Subero - University of Barcelona, Barcelona, Spain )
15 Jun 2018
Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results
Dr Olivier Casasnovas - CHU de Dijon, Dijon, France
Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results ( Dr Olivier Casasnovas - CHU de Dijon, Dijon, France )
15 Jun 2018
Repurposing selective PDE5 inhibitors as anti-cancer agents
Dr Pan Pantziarka - Anticancer Fund, Brussels, Belgium
Repurposing selective PDE5 inhibitors as anti-cancer agents ( Dr Pan Pantziarka - Anticancer Fund, Brussels, Belgium )
5 Jun 2018
First results of DREAM trial of frontline durvalumab for mesothelioma
Prof Anna Nowak - The University of Western Australia, Perth, Australia
First results of DREAM trial of frontline durvalumab for mesothelioma ( Prof Anna Nowak - The University of Western Australia, Perth, Australia )
5 Jun 2018
Results from the phase I ICONIC trial
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Results from the phase I ICONIC trial ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
4 Jun 2018
Phase II results of olaparib and abiraterone for mCRPC
Prof Noel Clarke - Salford Royal NHS Foundation Trust, Salford, UK
Phase II results of olaparib and abiraterone for mCRPC ( Prof Noel Clarke - Salford Royal NHS Foundation Trust, Salford, UK )
4 Jun 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation